Skip to main content
CL
NYSE Industrial Applications And Services

Reports Q4 & FY2025 Results with Significant Skin Health Impairment; Issues 2026 Guidance

Analysis by Wiseek AI
Sentiment info
Negative
Importance info
8
Price
$86.85
Mkt Cap
$68.709B
52W Low
$74.545
52W High
$100.18
Market data snapshot near publication time

Summary

Colgate-Palmolive reported a Q4 GAAP EPS loss and a full-year decline due to a $794 million skin health impairment charge, though underlying sales and non-GAAP EPS showed growth, and 2026 guidance is positive.


Key Events

  • Q4 GAAP EPS Loss

    Reported a fourth-quarter GAAP EPS loss of $(0.05), a 106% decline compared to the prior year, primarily due to an impairment charge.

  • Significant Impairment Charge

    Recorded a $794 million non-cash goodwill and intangible assets impairment charge in Q4 2025, related to the skin health business (primarily Filorga) due to underperformance.

  • Full Year GAAP EPS Decline

    Full year 2025 GAAP EPS decreased 25% to $2.63, impacted by the aforementioned impairment.

  • Underlying Business Growth

    Achieved Q4 net sales growth of 5.8% and organic sales growth of 2.2%, with Base Business (non-GAAP) EPS increasing 4% to $0.95.


Analysis

Colgate-Palmolive reported a substantial GAAP EPS loss for the fourth quarter and a significant decline for the full year 2025, primarily driven by a $794 million non-cash impairment charge related to its skin health business. This impairment, linked to lower-than-expected category growth and performance in China, signals challenges within that segment. Despite this, the company demonstrated underlying operational strength with positive net sales and organic sales growth, alongside an increase in non-GAAP (Base Business) EPS for both the quarter and full year. The forward-looking guidance for 2026, projecting net sales growth and double-digit GAAP EPS growth, suggests management anticipates a recovery and continued operational improvement, but the impairment remains a notable concern for the skin health portfolio.

At the time of this filing, CL was trading at $86.85 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $68.7B. The 52-week trading range was $74.55 to $100.18. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

CL - Latest Insights

CL
May 01, 2026, 4:06 PM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $87.00
Real-time Price: $89.59 info
Change: +$2.59 (+3%) info
Market Cap: $71.577B info
CL
May 01, 2026, 6:55 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $86.00
Real-time Price: $89.59 info
Change: +$3.59 (+4%) info
Market Cap: $71.577B info
CL
Mar 12, 2026, 4:33 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $87.80
Real-time Price: $89.59 info
Change: +$1.79 (+2%) info
Market Cap: $71.577B info
CL
Feb 23, 2026, 4:03 PM EST
Filing Type: 10-K
Importance Score:
8
Price at Filing: $97.10
Real-time Price: $89.59 info
Change: -$7.51 (-8%) info
Market Cap: $71.577B info
CL
Jan 30, 2026, 7:57 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $86.85
Real-time Price: $89.59 info
Change: +$2.74 (+3%) info
Market Cap: $71.577B info